The small but growing CD47 bispecific pipeline: Data Byte

Data presented at this year’s American Society of Clinical Oncology meeting showcased a growing pipeline of bispecific checkpoint inhibitors, including a handful targeting CD47. 

Using a bispecific construct to modulate two checkpoint targets instead of one may help overcome checkpoint inhibitor resistance, drive up efficacy and increase the proportion of patients who respond to the drug class. Bispecifics may also come with less toxicity than combinations of individual mAbs against checkpoints, because targeting two checkpoints on a tumor may better localize the immune-stimulating effect to the tumor microenvironment. ...